Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations

• Published in: Clinical diabetes and endocrinology Vol. 6; no. 1; pp. 1 - 18
• Main Authors: Brown, David R, East, Honey E, Eilerman, Bradley S, Gordon, Murray B, King, Elizabeth E, Knecht, Laura A, Salke, Brandon, Samson, Susan L, Yuen, Kevin C. J, Yau, Hanford
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 29-10-2020; BioMed Central; BMC
• Subjects: Arthritis; Blood pressure; Care and treatment; Cushing syndrome; Diabetes; Drug dosages; Drug effects; Drug withdrawal; Education; FDA approval; Glucocorticoids; Headaches; Hormones; Hypertension; Hypoglycemia; Metabolism; Mifepristone; Nausea; Patients; Progesterone; Review; Strategic planning (Business); Surgery; Type 2 diabetes; Ultrasonic imaging; Vagina; United States > US
• ISSN: 2055-8260; 2055-8260
• DOI: 10.1186/s40842-020-00105-4

Background While surgery is the first-line treatment for patients with endogenous hypercortisolism (Cushing syndrome [CS]), mifepristone has been shown to be a beneficial medical treatment option, as demonstrated in the SEISMIC (Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing Syndrome) trial. Mifepristone is a competitive glucocorticoid receptor antagonist and progesterone receptor antagonist that is associated with several treatment effects and adverse events that clinicians need to be aware of when considering its use. The objective of this review was to provide updated clinical management recommendations for patients with CS treated with mifepristone. Methods A panel of endocrinologists from the US with extensive experience in treating patients with CS, including with mifepristone, convened as part of a clinical advisory board to develop a consensus on the practical, real-world clinical management of patients on mifepristone. Results Comprehensive considerations and recommendations are provided for managing mifepristone-associated effects, including symptoms of cortisol withdrawal, hypokalemia, and change in thyroid function; effects related to its antiprogesterone activity; and rash. Additional management strategies to address concomitant medications and special clinical situations, such as surgery and use in specific populations, are also provided. Conclusion Safe and effective use of mifepristone requires clinical judgment and close patient monitoring to ensure optimal clinical outcomes. These consensus recommendations provide useful, practical guidance to clinicians using mifepristone. Keywords: Cushing syndrome, Drug effects, Education